Skip to main content

Table 1 Clinical and laboratory characteristics of patients

From: Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis

   All patients Anti-CCP P value
    Negative Positive  
Age <50* 45 (75%) 8 (17.8%) 37 (82.2%) NS
  ≥50 15 (25%) 2 (13.3%) 13 (86.7%)  
Sex female 54 (90%) 9 (16.7%) 45 (83.3%) NS
  male 6 (10%) 1 (16.7%) 5 (83.3%)  
Duration <6m 3 (5%) 1 (33.3%) 2 (66.7%) NS
  ≥6m 57 (95%) 9 (15.8%) 48 (84.2%)  
Smoking yes 5 (8.3%) 1 (20%) 4 (80%) NS
  no 55 (91.7%) 9 (16.4%) 46 (83.6%)  
CRP <18 * 26 (43.3%) 7 (26.9%) 19 (73.1%) NS
  ≥18 34 (56.7%) 3 (8.8%) 31 (91.2%)  
RF +ve 43 (71.7%) 4 (9.3%) 39 (90.7%) 0.02
    6 (35%) 11 (65%)  
ESR-1 <32 * 14 (23.3%) 5 (35.7%) 9 (64.3%) 0.04
  ≥32 46 (76.7%) 5 (10.9%) 41 (89.1%)  
ANA +ve 22 (36.7%) 0 (0%) 22 (100%) 0.03
  -ve 38 (63.3%) 10 (40.8%) 28 (59.2%)  
AKA +ve 31 (52%) 3 (10%) 28 (90%)  
  -ve 29 (48%) 17 (59%) 12 (41%) 0.05
Grade of activity (DAS)      
   - Mild or moderete   25 (41.7%) 9 (31.6%) 16 (68.4%) 0.001
   - Severe   35 (58.3%) 1 (9.8%) 34 (90.2%)  
Larsen score <35* 19 (31.7%) 6 (10%) 13 (21.7%) 0.05
  ≥35 41(68.3%) 4 (6.7%) 37 (61.7%)  
HLA-DRB1*04 +ve 21 (35%) 2 (9.5%) 19 (90.5%) NS
  -ve 39 (65%) 8 (20.5%) 31 (79.5%)  
HLA-RB1*01 +ve 27 (45%) 5 (19%) 22 (81%) NS
  -ve 33 (55%) 5 (15%) 28 (85%)  
  1. Values are expressed as n (%). AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides antibodies; ANA: antinuclear antibodies; DAS: disease activity score; CRP: C-reactive protein; RF: rheumatoid factor; HLA: human leukocyte antigen. * Cut-off values are medians.